Cancer

October 19, 2021

Combo therapy slows prostate cancer

A new combination treatment showed promise in slowing the growth of castration-resistant prostate cancer in animal models, Vanderbilt researchers discovered.

By Leigh MacMillan
Stomach
October 14, 2021

New marker for metaplasia

A protein that transports water, called aquaporin 5, is expressed by cells undergoing changes that may increase risk for gastric cancer development, Vanderbilt researchers discovered.

By Bill Snyder
Twenty-four hours after the administration of the study drug, catheters are inserted into the tumor and lasers emitting a wavelength of light that activates the dye molecule on the ASP-1929 are illuminated.
October 14, 2021

Photoimmunotherapy offered in clinical trial for recurrent head and neck cancer

Vanderbilt-Ingram Cancer Center is recruiting patients for a clinical trial using photoimmunotherapy for recurrent head and neck cancer.

By Tom Wilemon
September 30, 2021

Study shows how a protein coding gene confers breast cancer susceptibility during DNA transcription

Vanderbilt-Ingram Cancer Center research is providing new insights into how genetic variants convey breast cancer susceptibility by altering the transcription factor proteins that convert DNA strands into RNA.

By Tom Wilemon
September 24, 2021

Funding renewed for Meharry, TSU, Vanderbilt-Ingram partnership on cancer disparities

The Meharry Medical College/Vanderbilt-Ingram Cancer Center/Tennessee State University Partnership has received renewed funding from the NCI to continue long-standing collaborations to eliminate cancer health disparities.

By Tom Wilemon
September 23, 2021

Clinical trial tests ATR inhibitor in difficult-to-treat cancers

By Doug Campbell
September 23, 2021

Eng named co-chair of NCI clinical trials steering committee

Vanderbilt's Cathy Eng, MD, has been elected co-chair of the National Cancer Institute (NCI) Gastrointestinal Cancer Steering Committee.
By Tom Wilemon
September 21, 2021

The role of polarity in early cancer

Mutations in the protein epiregulin, an EGF receptor ligand, affect larger epithelial cell reorganization and may contribute to early cancer development, Vanderbilt researchers discovered.
By VUMC News and Communications
September 16, 2021

Structural variants in breast cancer risk genes

Vanderbilt epidemiologists conducted in-depth whole genome sequencing of breast cancer risk genes in Black women, who die at higher rates and have more aggressive disease, to discover mutations that may improve testing and treatment selection.
By Leigh MacMillan
September 16, 2021

Winkfield named to National Cancer Advisory Board

President Joe Biden has appointed Karen Winkfield, MD, PhD, to the National Cancer Advisory Board, where she will serve a six-year term and help guide federal initiatives that focus on cancer.
By Tom Wilemon
September 10, 2021

Novel immunotherapy shows robust response for multiple myeloma

Vanderbilt research found that a novel immunotherapy demonstrated robust effectiveness in treating relapsed or refractory multiple myeloma.
By Tom Wilemon
September 2, 2021

Using billing codes to count cancers

The billing codes in electronic health records are useful for counting skin cancers over time — an important metric for cancer risk assessment and prevention.
By Paul Govern
September 2, 2021

Discovery offers insight for development of cancer therapies targeting mutant p53

Vanderbilt researchers have discovered that aneuploidy (an abnormal number of chromosomes) drives malignant phenotypes in cells expressing mutant p53, a tumor suppressor protein that is mutated in more than half of all human cancers.
By Bill Snyder
1 … 15 16 17 18 19 … 65